her2-low mbc patients report preserved qol with trastuzumab deruxtecan
Published 1 year ago • 57 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
5:26
trastuzumab deruxtecan shows benefit in patients with her2 mbc
-
3:43
evolving role of trastuzumab deruxtecan in her2 /her2-low mbc
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
5:57
phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer patients
-
1:05
efficacy of trastuzumab deruxtecan in her2-low metastatic breast cancer
-
11:12
her2-low breast cancer: destiny or good science?
-
33:34
sharing my her2 breast cancer diagnosis story at 35 years old
-
24:38
stage 4 matastatic her 2 positive breast cancer third line enhertu and fourth line of treatment
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts
-
3:06
trastuzumab deruxtecan effective against brain metastases in her2-positive breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
7:13
overview of the management of her2-low breast cancer patients
-
4:03
trastuzumab deruxtecan significantly improves pfs in breast cancer patients previously treated w...
-
1:36
is her2-low a distinct subtype of breast cancer?
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
25:11
trastuzumab deruxtecan for her2-low metastatic breast cancer | dr. jitendra pahlajani
-
12:47
trastuzumab deruxtecan vs trastuzumab emtansine in patients with her2 metastatic breast cancer
-
7:39
asco 2022: trastuzumab deruxtecan vs. treatment of physician's choice in her2-low unresectable a...
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups